Algorithm for prescribing hormonal contraception and menopausal hormone therapy in perimenopause
I. I. Baranov,
E. N. Andreeva,
S. V. Yureneva,
M. I. Yarmolinskaya,
V. E. Balan,
E. I. Abashova,
N. V. Aganezova,
V. F. Bezhenar,
T. A. Gustovarova,
Yu. E. Dobrokhotova,
E. V. Yenkova,
L. Yu. Karakhalis,
N. Yu. Katkova,
A. E. Protasova,
I. V. Savelyeva,
Yu. A. Semenov,
T. M. Sokolova,
L. S. Sotnikova,
N. I. Tapliskaya,
M. B. Khamoshina,
E. V. Sheremetyeva https://doi.org/10.14341/brh12801
Abstract
The present algorithm has been created and proposed for clinical using due to collaboration of Russian society of obstetricians and gynecologists, Russian Association Of Endocrinologists, International Association of Obstetricians-Gynecologists and Endocrinologists, National Association of Obstetricians-Gynecologists and Reproductologists "Women’s Health", Interdisciplinary Association of Healthy Aging Specialists, Interdisciplinary Association of Reproductive Medicine Specialists "MARS", Society of Obstetricians and Gynecologists of St. Petersburg and the North-Western Region and Interdisciplinary Association of Specialists in Anti-Aging Medicine.
About the Authors
I. I. Baranov
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
Igor I. Baranov, MD, Doctor of Sciences, Professor
E. N. Andreeva
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov; Endocrinology Research Centre
Russian Federation
Russian Federation
Elena N. Andreeva, MD, Doctor of Sciences, professor
11 Dm. Ulyanova street, 117036 Moscow
S. V. Yureneva
National Medical Research Center for Obstetrics, Gynecology and Perinatology named after Academician V.I. Kulakov
Russian Federation
Russian Federation
Svetlana V. Yureneva, MD, PhD
M. I. Yarmolinskaya
D.O. Ott Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Mariya I. Yarmolinskaya, MD, Doctor of Sciences, Professor
V. E. Balan
MONIIAG
Russian Federation
Russian Federation
Vera E. Balan, MD, PhD, Professor
E. I. Abashova
D.O. Ott Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Elena I. Abashova, MD, PhD
N. V. Aganezova
North-Western State Medical University named after I.I. Mechnikov
Russian Federation
Russian Federation
Nataliya V. Aganezova, MD, Doctor of Sciences, Professor
V. F. Bezhenar
Pavlov First Saint Petersburg State Medical University
Russian Federation
Russian Federation
Vitaliy F. Bezhenar, MD, Doctor of Sciences, Professor
T. A. Gustovarova
Smolensk State Medical University
Russian Federation
Russian Federation
Tatyana A. Gustovarova, MD, Doctor of Sciences, Professor
Yu. E. Dobrokhotova
Pirogov Russian National Research Medical University
Yulia E. Dobrokhotova, MD, Doctor of Sciences, Professor
E. V. Yenkova
Voronezh State Medical University named after N.N. Burdenko
Russian Federation
Russian Federation
Elena V. Yenkova, MD, Doctor of Sciences, Professor
L. Yu. Karakhalis
Kuban State Medical University of Public Health Care of Russia
Russian Federation
Russian Federation
Lyudmila Yu. Karakhalis, MD, Doctor of Sciences, Professor
N. Yu. Katkova
Privolzhsky Research Medical University
Russian Federation
Russian Federation
Nadezhda Yu. Katkova, MD, Doctor of Sciences, Professor
A. E. Protasova
Almazov National Medical Research Centre
Russian Federation
Russian Federation
Anna E. Prostasova, MD, Doctor of Sciences, Professor
I. V. Savelyeva
Omsk State Medical Universityk
Russian Federation
Russian Federation
Irina V. Savelyeva, MD. Docro of Sciences
Yu. A. Semenov
Ural State Medical University
Russian Federation
Russian Federation
Yuriy A. Semenov, MD, Doctor of Sciences, Docent
T. M. Sokolova
Novosibirsk State Medical University
Russian Federation
Russian Federation
Tatyana M. Sokolova, MD, Doctor of Sciences, Professor
L. S. Sotnikova
Siberian State Medical University, Tomsk, Russia 18Medical Institute of RUDN Univeristy
Russian Federation
Russian Federation
Larisa S. Sotnikova, MD, Doctor of Sciences, Professor
N. I. Tapliskaya
D.O. Ott Research Institute of Obstetrics and Gynecology
Russian Federation
Russian Federation
Natalya I. Tapilskaya, MD, Doctor of Sciences
M. B. Khamoshina
Medical Institute of RUDN Univeristy
Russian Federation
Russian Federation
Marina B. Hamoshina, MD, Doctor of Sciences, Professor
E. V. Sheremetyeva
Endocrinology Research Centre
Russian Federation
Russian Federation
Ekaterina V. Sheremetyeva, MD, PhD
References
1. Bartz D., Tadikonda A., Manson J.E. Opportunity for improved menopausal hormone therapy prescribing. JAMA. 2026; 335(15): 1297-99. doi: https://dx.doi.org/10.1001/jama.2026.1891
2. Panay N., Ang S.B., Cheshire R., Goldstein S.R., Maki P., Nappi R.E. Menopause and MHT in 2024: addressing the key controversies - an International Menopause Society White Paper. Climacteric. 2024; 27(5): 441-57. doi: https://dx.doi.org/10.1080/13697137.2024.2394950
3. Письмо Министерства здравоохранения Российской Федерации от 8 апреля 2024 г. № 17-6/И/2-6434 «О направлении методических рекомендаций по диспансеризации мужчин и женщин репродуктивного возраста с целью оценки репродуктивного здоровья». Доступно по: https://www.garant.ru/products/ipo/prime/doc/408788357
4. Сухих Г.Т., Прилепская В.Н., ред. Национальные медицинские критерии приемлемости методов контрацепции. Адаптированный документ «Медицинские критерии приемлемости использования методов контрацепции ВОЗ, 5 издание, 2015». М.; 2023. 272 с.
5. Panay N., Fenton A., Hamoda H., Hillard T., Islam R., Pedder H. et al. International Menopause Society (IMS) recommendations and key messages on women’s midlife health and menopause. Climacteric. 2025; 28(6): 634-56. doi: https://dx.doi.org/10.1080/13697137.2025.2585487
6. Greendale G.A., Huang M., Cauley J.A., Matthews K.A., Gold E.B., Sowers M. et al. Trabecular bone score declines during the menopause transition: the Study of Women’s Health Across the Nation (SWAN). J. Clin. Endocrinol. Metab. 2019; 105(5): 1872-82. doi: https://dx.doi.org/10.1210/clinem/dgz056
7. Islam R.M., Bond M., Ghalebeigi A., Wang Y., Walker-Bone K., Davis S.R. Prevalence and severity of symptoms across the menopause transition: cross-sectional findings from the Australian Women’s Midlife Years (AMY) Study. Lancet Diabetes Endocrinol. 2025; 13(9): 765-76. doi: https://dx.doi.org/10.1016/S2213-8587(25)00138-X
8. Gold E.B., Crawford S.L., Avis N.E., Crandall C.J., Matthews K.A., Waetjen L.E. et al. Factors related to age at natural menopause: longitudinal analyses from SWAN. Am. J. Epidemiol. 2013; 178: 70-83. doi: https://dx.doi.org/10.1093/aje/kws421
9. Herber-Gast G.C., Mishra G.D., van der Schouw Y.T., Brown W.J., Dobson A.J. Risk factors for night sweats and hot flushes in midlife: results from a prospective cohort study. Menopause. 2013; 20(9): 953-9. doi: https://dx.doi.org/10.1097/GME.0b013e3182844a7c
10. Freeman E.W., Sammel M.D., Sanders R.J. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Aging Study cohort. Menopause. 2014; 21(9): 924-32. doi: https://dx.doi.org/10.1097/GME.0000000000000196
11. Panay N., Anderson R.A., Bennie A., Cedars M., Davies M., Ee C. et al. Evidence-based guideline: premature ovarian insufficiency. Climacteric. 2024; 27(6): 510-20. doi: https://dx.doi.org/10.1080/13697137.2024.2423213
12. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Менопауза и климактерическое состояние у женщины. 2025.
13. Harlow S.D., Gass M., Hall J.E., Lobo R., Maki P., Rebar R.W. et al. Executive summary of the Stages of reproductive aging workshop +10: addressing the unfinished agenda of staging reproductive aging. Menopause. 2012; 19(4): 387-95. doi: https://dx.doi.org/10.1097/gme.0b013e31824d8f40
14. Verrilli L., Berga S.L. What every gynecologist should know about perimenopause. Clin. Obstet. Gynecol. 2020; 63(4): 720-34. doi: https://dx.doi.org/10.1097/GRF.0000000000000578
15. Davis S.R., Taylor S., Hemachandra C., Magraith K., Ebeling P.R., Jane F. et al. The 2023 Practitioner’s toolkit for managing menopause. Climacteric. 2023; 26(6): 517-36. doi: https://dx.doi.org/10.1080/13697137.2023.2258783
16. Prior J.C. Perimenopause: the complex endocrinology of the menopausal transition. Endocr. Rev. 1998; 19(4): 397-428. doi: https://dx.doi.org/10.1210/edrv.19.4.0341
17. Hall J.E. Endocrinology of the menopause. Endocrinol. Metab. Clin. N. Am. 2015; 44(3): 485-96. doi: https://dx.doi.org/10.1016/j.ecl.2015.05.010
18. Lumsden M.A., Dekkers O.M., Faubion S.S., Hirschberg A.L., Jayasena C.N., Lambrinoudaki I. et al. European Society of Endocrinology clinical practice guideline for evaluation and management of menopause and the perimenopause. Eur. J. Endocrinol. 2025; 193(4): G49-81. doi: https://dx.doi.org/10.1093/ejendo/lvaf206
19. Santoro N., Lasley B., McConnell D., Allsworth J., Crawford S., Gold E.B. et al. Body size and ethnicity are associated with menstrual cycle alterations in women in the early menopausal transition: the Study of Women’s Health across the Nation (SWAN) daily hormone study. J. Clin. Endocrinol. Metab. 2004; 89(6): 2622-31. doi: https://dx.doi.org/10.1210/jc.2003-031578
20. Perry J.R.B., Murray A., Day F.R., Ong K.K. Molecular insights into the aetiology of female reproductive ageing. Nat. Rev. Endocrinol. 2015; 11(12): 725-34. doi: https://dx.doi.org/10.1038/nrendo.2015.167
21. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Гиперплазия эндометрия. 2025.
22. Министерство здравоохранения Российской Федерации. Клинические рекомендации. Аномальные маточные кровотечения. 2024.
23. Santoro N., Brown J.R., Adel T., Skurnick J.H. Characterization of reproductive hormonal dynamics in the perimenopause. J. Clin. Endocrinol. Metab. 1996; 81(4): 1495-501. doi: https://dx.doi.org/10.1210/jcem.81.4.8636357
24. Gordon J.L., Girdler S.S., Meltzer-Brody S.E., Stika C.S., Thurston R.C., Clark C.T. et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal depression: a novel heuristic model. Am. J. Psychiatry. 2015; 172(3): 227-36. doi: https://dx.doi.org/10.1176/appi.ajp.2014.14070918
25. Conklin M., Santoro N. Neurokinin receptor antagonists as potential non-hormonal treatments for vasomotor symptoms of menopause. Ther. Adv. Reprod. Health. 2023; 17: 26334941231177611. doi: https://dx.doi.org/10.1177/26334941231177611
26. Young Moss S., Lee A., Simon J.A. Advances in pharmacotherapy for menopausal vasomotor symptoms. Drugs. 2025; 85(11): 1363-79. doi: https://dx.doi.org/10.1007/s40265-025-02231-8
27. Santoro N., Epperson C.N., Mathews S.B. Menopausal symptoms and their management. Endocrinol. Metab. Clin. North Am. 2015; 44(3): 497-515. doi: https://dx.doi.org/10.1016/j.ecl.2015.05.001
28. Davis S.R., Lambrinoudaki I., Lumsden M., Mishra G.D., Pal L., Rees M. et al. Menopause. Nat. Rev. Dis. Primers. 2015; 1: 15004. doi: https://dx.doi.org/10.1038/nrdp.2015.4
29. Coslov N., Richardson M.K., Woods N.F. «Not feeling like myself» in perimenopause - what does it mean? Observations from the Women Living Better survey. Menopause. 2024; 31(5): 390-8. doi: https://dx.doi.org/10.1097/GME.0000000000002339
30. Bremer E., Jallo N., Rodgers B., Kinser P., Dautovich N. Anxiety in menopause: a distinctly different syndrome? J. Nurse Pract. 2019; 15(5): 374-8. doi: https://dx.doi.org/doi.org/10.1016/j.nurpra.2019.01.018
31. Gordon J.L., Girdler S.S., Meltzer-Brody S.E., Stika C.S., Thurston R.C., Clark C.T. et al. Ovarian hormone fluctuation, neurosteroids, and HPA axis dysregulation in perimenopausal. depression: a novel heuristic model. Am. J. Psychiatry. 2015; 172(3): 227-36. doi: https://dx.doi.org/10.1176/appi.ajp.2014.14070918
32. Zheng Y., Manson J.E., Yuan C., Liang M.H., Grodstein F., Stampfer M.J. et al. Associations of weight gain from early to middle adulthood with major health outcomes later in life. JAMA. 2017; 318(3): 255-69. doi: https://dx.doi.org/10.1001/jama.2017.7092
33. Greendale G.A., Sternfeld B., Huang M., Han W., Karvonen-Gutierrez C., Ruppert K. et al. Changes in body composition and weight during the menopause transition. JCI Insight. 2019; 4(5): e124865. doi: https://dx.doi.org/10.1172/jci.insight.124865
34. Shlyakhto E.V., Dedov I.I., Serov V.N., Sukhikh G.T., Arutyunov G.P., Suchkov I.A. Russian eligibility criteria for prescription of menopausal hormone therapy to patients with cardiovascular and metabolic diseases. Agreement document of RKO, ROAG, RAE, EAT, AFR2023; 11: 211-32. doi: https://dx.doi.org/10.18565/aig.2023.267 (In Russ.).
35. Joint position of Russian experts on the clinical significance of hyperandrogenism in early postmenopausal women. Obstetrics and gynecology. 2025;5:201–6 (In Russ.). doi: https://dx.doi.org/10.18565/aig.2025.118
36. Ling J., Wang Y.H. Association between depressive mood and body image and menopausal symptoms and sexual function in perimenopausal women. World J. Clin. Cases. 2023; 11(32): 7761-9. doi: https://dx.doi.org/10.12998/wjcc.v11.i32.7761
37. Saleh S.A., Almadani N., Mahfouz R., Nofal H.A., El-Rafey D.S., Seleem D.A. Exploring the intersection of depression, anxiety, and sexual health in perimenopausal women. Int. J. Womens Health. 2024; 16: 1315-27. doi: https://dx.doi.org/10.2147/IJWH.S464129
38. Tiwari M., Acharya N., Mahakarkar M. Navigating the vaginal milieu during perimenopause: a narrative review of physiological changes and clinical implications. J. Pharm. Bioallied Sci. 2025; 17(Suppl 1): S92-5. doi: https://dx.doi.org/10.4103/jpbs.jpbs_1493_24
39. North American Menopause Society. Menopause practice. Clinician’s guide. 6th ed.; 2025. Available at: https://menopause.org/professional-resources/menopause-practice-textbook. Yureneva S., Komedina V., Kuznetsov S. COCs with estradiol valerate/dienogest vs 17β estradiol/nomegestrol acetate: effects on metabolism and body composition in menopausal transition women. Maturitas. 2023; 173: 76-7.
40. Kim Y., Cho M.K., Chung Y.J., Hong S.H., Hwang K.R., Jeon G.H. et al.; Publication Committee on Clinical Guidelines of the Korean Society of Menopause. The 2025 Menopausal Hormone Therapy Guidelines - Korean Society of Menopause. J. Menopausal Med. 2025; 31(2): 53-84. doi: https://dx.doi.org/10.6118/jmm.25103
41. Fruzzetti F., Trémollieres F., Bitzer J. An overview of the development of combined oral contraceptives containing estradiol: focus on estradiol valerate /dienogest. Gynecol. Endocrinol. 2012; 28(5): 400-8. doi: https://dx.doi.org/10.3109/09513590.2012.662547
42. Macìas G., Merki-Feld G.S., Parke S., Mellinger U., Serrani M. Effects of a combined oral contraceptive containing oestradiol valerate/dienogest on hormone withdrawal-associated symptoms: results from the multicentre, randomised, double-blind, active-controlled HARMONY II study. J. Obstet. Gynaecol. 2013; 33(6): 591-6. doi: https://dx.doi.org/10.3109/01443615.2013.800851
43. Общая характеристика лекарственного препарата Клайра® от 31.05.2023. Доступно по: https://www.rlsnet.ru/drugs/klaira-40216
44. Paoletti A.M., Lello S., Di Carlo C., Orrù M., Malune M.E., Neri M. et al. Effect of estradiol valerate plus dienogest on body composition of healthy women in the menopausal transition: a prospective one-year evaluation. Gynecol. Endocrinol. 2016; 32(1): 61-4. doi: https://dx.doi.org/10.3109/09513590.2015.1079175
45. Davis S.R., Bitzer J., Giraldi A., Palacios S., Parke S., Serrani M. et al. Change to either a nonandrogenic or androgenic progestin-containing oral contraceptive preparation is associated with improved sexual function in women with oral contraceptive-associated sexual dysfunction. J. Sex. Med. 2013; 10(12): 3069-79. doi: https://dx.doi.org/10.1111/jsm.12310
46. Caruso S., Agnello C., Romano M., Cianci S., Lo Presti L., Malandrino C. et al. Preliminary study on the effect of four-phasic estradiol valerate and dienogest (E2V/DNG) oral contraceptive on the quality of sexual life. J. Sex. Med. 2011; 8(10): 2841-50. doi: https://dx.doi.org/10.1111/j.1743-6109.2011.02409.x
47. Karachentsev A.N., Melnichenko G.A. Choice of optimal gestagen for combined hormonal replacement therapy in the peri- and postmenopause. Problems of Endocrinology. 2006;52(2):7-16. (In Russ.) doi: https://doi.org/10.14341/probl20065227-16
48. Общая характеристика лекарственного препарата Евра® от 22.08.2025. Доступно по: https://www.vidal.ru/drugs/evra__6659?ysclid=moo86xvxdz170506629
49. Общая характеристика лекарственного препарата Мирена® от 03.02.2026. Доступно по: https://www.vidal.ru/drugs/mirena__440?ysclid=moo8okzi4u749067901
50. Общая характеристика лекарственного препарата Кайлина® ЛНГ от 15.04.2024. Доступно по: https://www.vidal.ru/drugs/kailina-lng?ysclid=moo8u35u2u368165087
51. Общая характеристика лекарственного препарата Фемостон® 1 от 16.09.2025. Доступно на: https://www.vidal.ru/drugs/femoston_1_10__1276?ysclid=moo8yj965j547226292
52. Общая характеристика лекарственного препарата Фемостон® 2 от 18.09.2025. Доступно по: https://www.vidal.ru/drugs/femoston_2_10__1275?ysclid=moo92s7tyw957576857
Review
For citations:
Baranov I.I., Andreeva E.N., Yureneva S.V., Yarmolinskaya M.I., Balan V.E., Abashova E.I., Aganezova N.V., Bezhenar V.F., Gustovarova T.A., Dobrokhotova Yu.E., Yenkova E.V., Karakhalis L.Yu., Katkova N.Yu., Protasova A.E., Savelyeva I.V., Semenov Yu.A., Sokolova T.M., Sotnikova L.S., Tapliskaya N.I., Khamoshina M.B., Sheremetyeva E.V. Algorithm for prescribing hormonal contraception and menopausal hormone therapy in perimenopause. Bulletin of Reproductive Health. 2026;5(2):27-39. (In Russ.) https://doi.org/10.14341/brh12801
Views:
37
JATS XML
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
